'Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.

Dickson, S P; Wessels, A M; Dowsett, S A; Mallinckrodt, C; Sparks, J D; Chatterjee, S; Hendrix, S

Dickson, S P; Wessels, A M; Dowsett, S A; Mallinckrodt, C; Sparks, J D; Chatterjee, S; Hendrix, S.

Affiliation

Dickson SP; Alette M Wessels, Eli Lilly and Company, Indianapolis, IN, USA, E-mail: wessels_alette_maria@lilly.com, Tel: 317-276-9502.

J Prev Alzheimers Dis ; 10(3): 595-599, 2023.

Article in En | MEDLINE | ID: mdl-37357301

Subject(s)

Alzheimer Disease; Humans; Alzheimer Disease/diagnosis; Alzheimer Disease/drug therapy; Treatment Outcome; Antibodies, Monoclonal/therapeutic use; Mental Status and Dementia Tests; Disease Progression

Key words

Alzheimer's disease; Clinical trial; iADRS; slowing of disease progression; time component test

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease Type of study: Clinical_trials / Diagnostic_studies Limits: Humans Language: En Journal: J Prev Alzheimers Dis Year: 2023 Type: Article

Fulltext

XML

PubMed Links

Search on Google